TrialSignal transduction and targeted therapy2025

Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).

Chengqiang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.